CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase
CervoMed soared over 30% premarket after an SEC filing revealed a trust linked to board chair Joshua S. Boger bought $3 million in units above Monday’s close, signaling insider confidence following last week’s $10.5 million private placement that extends cash runway but raises dilution risks; the next key catalyst is securing a strategic partner for neflamapimod’s Phase 3 dementia with Lewy bodies program.